Pharmacodynamics Calculator — EC50, Emax, Therapeutic Index

Calculate therapeutic index, drug effect using the Emax model, and absolute or relative bioavailability — the core pharmacodynamic parameters used in clinical pharmacology and pharmacy education.

Created by Ashar PervaizMedically reviewed by Dr. Syeda Khadija AkbarLast reviewed 14 October 2026

One Curve Underneath All of It

Almost every pharmacodynamic quantity is a description of the same picture: a graph of drug concentration against the effect it produces. Plotted against the logarithm of concentration, that relationship takes an S shape — little effect at low concentrations, a steep middle section where small increases produce large changes, and a plateau where adding more drug achieves nothing further.

Once you can see that curve, the parameters stop being a list to memorise and become features of it:

Two parameters therefore define a drug's basic pharmacodynamic character: how far along the axis the curve sits, and how high it rises. They are independent of one another, which is where most confusion in this topic originates.

Potency and Efficacy Are Not the Same Question

These two are conflated constantly in ordinary speech and separated rigorously in pharmacology, and the distinction is worth getting exactly right because it appears in almost every exam on the subject.

Potency is about dose. A more potent drug achieves a given effect at a lower concentration — its curve sits further left. It is measured by EC50 or ED50, and a lower value means greater potency.

Efficacy is about ceiling. A drug with greater efficacy produces a larger maximum effect, however much of it you give — its curve plateaus higher. It is measured by Emax.

A drug can be highly potent and have low efficacy: tiny doses do something, but that something never amounts to much. Another can be weakly potent yet highly efficacious: it takes a large dose, and at that dose it does a great deal. Clinically, efficacy usually decides whether a drug is worth using at all; potency mostly decides the size of the tablet.

Comparing potencies is only meaningful between drugs producing the same effect through a comparable mechanism. Comparing the EC50 of a painkiller with that of an antihypertensive is arithmetic without meaning.

Reading the Emax Model

The Emax equation is the algebraic form of the curve:

Effect = (Emax × C) ÷ (EC50 + C)

Substituting C = EC50 gives Effect = Emax ÷ 2, which is the definition of EC50 restated: the concentration producing half the maximum effect.

The equation carries a consequence with real clinical weight. Once concentration is well above EC50, the denominator is dominated by C and the fraction approaches one, so effect approaches Emax and stops responding to further increases. Doubling the dose at that point adds essentially no benefit — while the mechanisms producing side effects, which have their own separate curves, may still be climbing steeply.

This is the pharmacological reason that pushing a dose past the point of adequate response tends to buy toxicity rather than efficacy.

Three Doses, Three Different Populations

ED50, TD50 and LD50 are structurally identical measures applied to different endpoints, and the shared "50" refers to the proportion of a population, not to a proportion of effect.

• ED50 — the dose producing the desired therapeutic effect in half the population tested.
• TD50 — the dose producing a defined toxic effect in half the population.
• LD50 — the dose that is lethal in half the animals tested, a preclinical toxicology measure rather than a clinical one.

The population framing matters. An ED50 does not mean each individual gets half an effect; it means half the individuals respond. Everything derived from these figures inherits that population basis, which is precisely why they cannot be applied to a single patient in front of you.

What a Therapeutic Index Actually Buys You

Therapeutic index = TD50 ÷ ED50

A larger ratio means a wider gap between the dose that helps and the dose that harms. A drug with a TI of 100 has considerable margin; one with a TI near 2 has almost none, and small errors in dose, absorption or clearance can cross from therapy into toxicity.

Three qualifications keep the number in proportion.

First, the index compares two midpoints and says nothing about the curves' steepness. If the toxicity curve rises very sharply, a respectable-looking index can still describe a drug where a small overshoot produces sudden harm. Two drugs with the same TI are not necessarily equally forgiving.

Second, both figures are population averages. Individual variation in absorption, protein binding, clearance and receptor sensitivity means a particular patient may sit far from either midpoint, which is why narrow-index drugs are managed with concentration monitoring rather than by trusting the ratio.

Third, a high therapeutic index is not a synonym for safety. It addresses the relationship between dose and one defined toxic endpoint. Allergic reactions, idiosyncratic responses and drug interactions are not dose-related in this sense and sit entirely outside what the index describes.

Agonists, Partial Agonists and Antagonists on the Same Axes

The curve also distinguishes the main receptor behaviours without needing separate definitions.

A full agonist produces the maximum response the system can generate — its curve plateaus at the top. A partial agonist binds the same receptor but plateaus lower no matter how much is present, so it has a ceiling below the full agonist's regardless of potency. A competitive antagonist produces no effect alone; its presence shifts an agonist's curve to the right, meaning more agonist is needed for the same effect, while the achievable maximum is unchanged.

The partial agonist case has a consequence students often find counter-intuitive: in the presence of a full agonist, a partial agonist can behave as an antagonist, because it occupies receptors while producing less effect than the drug it displaced.

Where Bioavailability Fits

Bioavailability is a pharmacokinetic quantity, but it is calculated here because it sits directly between a dose and the concentration that produces an effect.

Absolute F = (AUC oral ÷ AUC intravenous) × (Dose IV ÷ Dose oral)

Intravenous administration is the reference because none of the dose is lost. Any other route loses some fraction to incomplete absorption and to first-pass metabolism in gut wall and liver, so oral doses are usually larger than their intravenous equivalents for the same exposure.

Relative bioavailability compares two non-intravenous formulations rather than against an intravenous standard, and is the basis of bioequivalence testing for generics — the question there is not whether a formulation is well absorbed in absolute terms, but whether it behaves closely enough to the reference product.

For half-life, volume of distribution, clearance and the dose calculations that use them, see the pharmacokinetics calculator. For converting a decided dose into an administered amount, the dosage calculator handles weight-based orders.

Pharmacodynamics Questions From the Exam Room

Educational reference only. Confirm any clinical calculation independently before acting on it. How this page is reviewed